期刊文献+

幽门螺杆菌疫苗诱导的免疫保护反应及临床试验研究进展 预览

Progress in protective immune response induced by Helicobacter pylori vaccine and related clinical trials
在线阅读 下载PDF
分享 导出
摘要 幽门螺杆菌(Helicobacterpylori,Hp)是一种微需氧、寄生于胃黏膜表面的革兰阴性致病菌,可导致各种不同的疾病,如慢性活动性胃炎、胃和十二指肠溃疡,甚至包括胃黏膜相关淋巴样组织(mucosa-associatedlymphoidtissue,MALT)淋巴瘤和胃腺癌等恶性疾病。目前根除Hp主要依靠包括2种抗生素、铋剂和质子泵抑制剂(protonpumpinhibitors,PPI)在内的四联疗法。随着Hp耐药性的增强,研发Hp疫苗成为防治Hp感染的新途径。Hp疫苗能够诱导机体产生抗原特异性血清IgG和黏膜sIgA体液免疫反应以及抗原特异性CD4+T细胞免疫反应等的有效免疫保护反应。 Helicobacter pylori (Hp) is a gram negative pathogenic bacterium which is micro-aerobic and parasitic on the surface of the gastric mucosa. It can lead to a variety of different diseases, such as chronic active gastritis, gastric and duodenal ulcers, and even malignant diseases, including gastric mucosa associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma. The eradication of Hp is mainly based on quadruple therapy containing two antibiotics, bismuth and proton pump inhibitors(PPI). With the increase of the resistance of Hp, the development of Hp vaccine has become a new way to prevent and treat the Hp infection. Hp vaccine can induce the effective immune response in the body including antigen specific serum IgG and mucosa sIgA antibody immune response and antigen specific CD4 + T cell immune response. This article reviews the immune protection reaction induced by Hp vaccine and the results of the related clinical trials.
作者 张鑫(综述) 刘纯杰(审校) ZHANG Xin;LIU Chun-jie(Laboratory of Microorganism Engineering, Institute of Biotechnology, Academy ofMilitary Medical Sciences, Beijing 100071, China)
出处 《微生物学免疫学进展》 2019年第1期73-78,共6页 Progress In Microbiology and Immunology
基金 “艾滋病和病毒性肝炎等重大传染病防治”科技重大专项课题(2018ZX10101003-005-005).
关键词 幽门螺杆菌 疫苗 免疫保护 临床试验 Helicobacter pylori (Hp) Vaccine Immune protection Clinical trials
作者简介 张鑫(1985-),女,博士研究生,主要从事幽门螺杆菌疫苗免疫保护机制的研究;通信作者:刘纯杰,研究员,E-mail:liucj@bmi.ac.cn.
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈